LARGE B-CELL LYMPHOMA

This study tests a new cell therapy called ronde-cel that targets two proteins (CD19 and CD20) on lymphoma cells, compared to standard CAR T-cell therapy that targets only one. About 400 adults with large B-cell lymphoma that came back or didn't respond to first treatment will ta…

This study is testing a new drug called AZD0486, either by itself or with other cancer treatments, in people with certain types of blood cancers like chronic lymphocytic leukemia and lymphoma. The main goals are to check if the drug is safe and to find the best dose. About 408 pa…

This study is testing whether a second dose of a CAR T-cell therapy called Axi-Cel is safe for people with a type of blood cancer called large B-cell lymphoma that is hard to treat. About 20 adults who have already had standard CAR T treatment but are at high risk of their cancer…

This study tests a new treatment called cemacabtagene ansegedleucel (cema-cel) for adults with large B-cell lymphoma who have tiny amounts of cancer left after their first round of therapy. About 250 participants will either receive cema-cel (a type of CAR T cell therapy made fro…

This early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…

This study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not responded to at least two prior therapies. The therapy uses a patient's own immune cells, which are modified to recognize and attack two markers on cancer cells …

This early-stage study tests an experimental drug (UB-VV400) alone and with rapamycin in adults with aggressive B-cell lymphoma that has returned or not responded to treatment. About 70 participants will receive the therapy to find the safest dose and check for side effects. The …

This study tests whether a personalized cell therapy called liso-cel can prevent large B-cell lymphoma from returning in patients who still have signs of the disease after standard treatment. About 10 adults whose cancer is in remission but who test positive for lymphoma DNA will…

This early-phase study tests a drug called NT-I7 (a long-acting immune booster) given after standard CAR T-cell therapy for people with relapsed or hard-to-treat large B-cell lymphoma. The goal is to see if NT-I7 is safe and can help CAR T-cells grow and last longer in the body, …

This study tests whether combining two drugs, epcoritamab and loncastuximab tesirine, can safely shrink or eliminate lymphoma in people whose cancer has returned or stopped responding to treatment. About 26 adults with relapsed or refractory large B-cell lymphoma will receive the…

This study tests whether giving focused radiation to large tumors before CAR-T cell therapy can improve outcomes for people with aggressive large B-cell lymphoma that has come back or not responded to treatment. About 27 participants will receive the radiation followed by standar…

This study tests whether giving an extra antibody drug (mosunetuzumab or glofitamab) after standard CAR-T cell therapy can improve outcomes for people with aggressive large B-cell lymphoma that has returned or not responded to prior treatments. About 42 participants will receive …

This early study looks at whether a supplement called beta-hydroxybutyrate (BHB) is safe and tolerable for people with large B-cell lymphoma who are receiving standard CAR-T cell therapy. Five adults will take the supplement by mouth during their treatment. Researchers will also …

This study reviews medical records from about 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. Researchers want to see how well the drug controls the cancer and what side effects occur, especially in patients whose…

This study tests whether adding the drug epcoritamab to a standard low-dose chemo mix can help control newly diagnosed diffuse large B-cell lymphoma in adults who are older, frail, or cannot take stronger chemo. About 40 participants will receive the combination and be monitored …

This study tests whether the drug loncastuximab tesirine can help people with large B-cell lymphoma who had only a partial response to CAR T-cell therapy achieve a complete remission. About 30 adults whose lymphoma returned or didn't fully respond after CAR T will receive the stu…

This study tests whether a shorter course of chemotherapy followed by a targeted drug called AZD0486 works as well as the full standard chemo regimen for older or frail adults newly diagnosed with large B-cell lymphoma. About 420 participants will be randomly assigned to one of t…

This study gives patients with large B-cell lymphoma or follicular lymphoma access to a CAR T-cell therapy called axicabtagene ciloleucel, even when their specific batch didn't meet commercial quality standards. The treatment is still considered safe and effective enough for use …

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy. It enrolls 28 adults with certain types of relapsed or refractory large B-cell lymphoma who are receiving standard CAR-T treatm…

This study tests whether a combination of two drugs, tafasitamab and lenalidomide, can help people with large B-cell lymphoma that did not fully go away after a type of immunotherapy called CAR-T. The study will enroll 28 adults and follow them for about 12 months to see if the c…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This study tests a new treatment called CTX112 for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor immune cells that can target and kill cancer cells. The trial…

This early-phase study is testing whether it is safe and possible to collect a patient's own stem cells and give them together with CAR T-cell therapy for blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain types of lymphoma…

This study tests a combination of three drugs (glofitamab, a PD-1 inhibitor, and lenalidomide) in 24 people with a type of large B-cell lymphoma that has returned or not responded to treatment and has a specific gene change (TP53). The goal is to see if this combination can shrin…

This trial tests a new treatment called WZTL-002 for people with large B-cell lymphoma that came back or didn't get better after standard chemo. It uses the patient's own immune cells, modified to fight cancer, and is given as a one-time infusion. About 60 adults aged 18 to 75 wi…

This study is developing and testing a communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors talk with patients about their diagnosis and plan future care. About 48 people (doctors and patients) will take part…

This study aims to find out which patient and tumor features help predict whether CAR-T therapy will work for people with relapsed or hard-to-treat large B-cell lymphoma. Researchers will analyze data from 80 participants to look for patterns. The goal is to better understand who…